EyePoint Pharmaceuticals, Inc.
Organization
EyePoint Pharmaceuticals is a biopharmaceutical company specializing in the development and commercialization of innovative ophthalmic products. The company leverages its proprietary drug delivery technologies, such as Durasert, to design sustained-release therapeutics for serious retinal diseases.
What experts have said about EyePoint Pharmaceuticals, Inc.
2 statements · 1 negative · 1 mixed
EyePoint’s experimental eye-disease treatment failed its late-stage primary endpoint.
“the drug developer said its experimental treatment for an eye disease failed to meet a primary goal in its late stage trial.”
Open the episode · Closing Bell: Chip Stocks Rise, SpaceX Gains, EyePoint SinksListen at 3:15
EyePoint’s failed trial does not necessarily end its prospects.
“that doesn't necessarily mean this is the end.”
Open the episode · Closing Bell: Chip Stocks Rise, SpaceX Gains, EyePoint SinksListen at 3:46
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
2 episodes featuring EyePoint Pharmaceuticals, Inc.
Stock Movers
AI chip rally collides with biotech failure and bond-market stress
The market close shows how enthusiasm for AI-linked growth can coexist with sharp losses in drug development and rising pressure on bonds.
Aug 17, 2026 · 8 min
Stock Movers
Anthropic lifts SanDisk as EyePoint and Snap lose ground
The episode shows how company-specific catalysts—from AI-linked revenue to trial failures, insider selling, and litigation—can drive sharply different stock moves.
Aug 17, 2026 · 5 min